Immix Biopharma (NASDAQ:IMMX) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Immix Biopharma (NASDAQ:IMMX) posted its earnings results on Tuesday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08), Zacks reports.

Immix Biopharma Trading Up 3.2 %

Immix Biopharma stock opened at $1.62 on Friday. The stock has a market cap of $44.57 million, a P/E ratio of -1.91 and a beta of 0.11. The company has a 50-day moving average price of $1.65 and a 200 day moving average price of $1.97. Immix Biopharma has a 12-month low of $1.26 and a 12-month high of $7.75.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Immix Biopharma in a research report on Thursday, October 3rd.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.